Adial Pharmaceuticals’ (ADIL) “Sell (E+)” Rating Reiterated at Weiss Ratings

Weiss Ratings restated their sell (e+) rating on shares of Adial Pharmaceuticals (NASDAQ:ADIL) in a research report report published on Wednesday,Weiss Ratings reports.

Several other equities research analysts also recently weighed in on ADIL. Maxim Group raised shares of Adial Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.50 target price on the stock in a research note on Tuesday, September 30th. Zacks Research cut shares of Adial Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, August 20th. Finally, Wall Street Zen upgraded shares of Adial Pharmaceuticals to a “sell” rating in a report on Saturday, July 26th. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and an average target price of $4.75.

Adial Pharmaceuticals Stock Down 9.0%

Shares of ADIL opened at $0.38 on Wednesday. Adial Pharmaceuticals has a fifty-two week low of $0.22 and a fifty-two week high of $1.30. The firm’s 50 day moving average price is $0.37 and its 200 day moving average price is $0.50. The company has a market cap of $8.33 million, a P/E ratio of -0.36 and a beta of 1.36.

Adial Pharmaceuticals (NASDAQ:ADIL) last announced its earnings results on Wednesday, August 13th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.22) by $0.04. Research analysts forecast that Adial Pharmaceuticals will post -1.53 earnings per share for the current year.

Institutional Inflows and Outflows

A hedge fund recently raised its stake in Adial Pharmaceuticals stock. Citadel Advisors LLC grew its stake in Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) by 63.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 54,508 shares of the company’s stock after buying an additional 21,238 shares during the period. Citadel Advisors LLC owned 0.85% of Adial Pharmaceuticals worth $55,000 at the end of the most recent reporting period. Institutional investors and hedge funds own 16.41% of the company’s stock.

About Adial Pharmaceuticals

Adial Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment or prevention of addiction and related disorders. Its lead product is AD04, a serotonin-3 antagonist, which is in Phase III clinical trial for the treatment of alcohol use disorder.